ISSN: 0022-2623

Journal Home

Journal Guideline

Journal of Medicinal Chemistry Q1 Unclaimed

American Chemical Society United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Medicinal Chemistry is a journal indexed in SJR in Drug Discovery and Molecular Medicine with an H index of 276. It has a price of 3678 €. It has an SJR impact factor of 1.888 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1.888.

Journal of Medicinal Chemistry focuses its scope in these topics and keywords: inhibitors, activity, synthesis, evaluation, derivatives, biological, receptor, potent, selective, agents, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Drug Discovery (Q1) Molecular Medicine (Q1)

Price

3678 €

Inmediate OA

1839 €

Embargoed OA

0 €

Non OA

Metrics

1.888

SJR Impact factor

276

H Index

1045

Total Docs (Last Year)

2341

Total Docs (3 years)

67515

Total Refs

18367

Total Cites (3 years)

2322

Citable Docs (3 years)

7.64

Cites/Doc (2 years)

64.61

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Perspectives in Medicinal Chemistry Q1
Molecular Therapy Q1
Emerging Microbes and Infections Q1
Natural Product Reports Q1
Cell Chemical Biology Q1

Compare this journals

Aims and Scope

Best articles by citations

Influence of Various Central Moieties on the Hypolipidemic Properties of Long Hydrocarbon Chain Diols and Diacids

Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors

Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design

Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension

Guttiferone A Aggregates Modulate Silent Information Regulator 1 (SIRT1) Activity

The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features

Biophysical Characterization of Zinc Ejection from HIV Nucleocapsid Protein by Anti-HIV 2,2'-Dithiobis[benzamides] and Benzisothiazolones

No Denying It: Medicinal Chemistry Training Is in Big Trouble

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

AnN,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease

Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1

Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine beta-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors

SHOW MORE ARTICLES

Synthesis, Structure-Activity Relationships, and Biological Studies of Chromenochalcones as Potential Antileishmanial Agents

Pharmacophore Model To Discover OX1 and OX2 Orexin Receptor Ligands

Substituted 2-Thioxoimidazolidin-4-ones and Imidazolidine-2,4-diones as Fatty Acid Amide Hydrolase Inhibitors Templates

Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists

Crystallographic Investigation of the Inhibition Mode of a VIM-2 Metallo-beta-lactamase fromPseudomonas aeruginosaby a Mercaptocarboxylate Inhibitor

Structure-Activity Relationship of 6-Methylidene Penems Bearing Tricyclic Heterocycles as Broad-Spectrum beta-Lactamase Inhibitors: Crystallographic Structures Show Unexpected Binding of 1,4-Thiazepine Intermediates

Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor

Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors

Structure-Activity Relationship Studies of Nordihydroguaiaretic Acid Inhibitors toward Soybean, 12-Human, and 15-Human Lipoxygenase

Structure-Activity Relationship Studies To Identify Affinity Probes in Bis-aryl Sulfonamides That Prolong Immune Stimuli

Synthesis of131I-Labeled Glucose-Conjugated Inhibitors ofO6-Methylguanine-DNA Methyltransferase (MGMT) and Comparison with Nonconjugated Inhibitors as Potential Tools for in Vivo MGMT Imaging

Structure-Activity Relationships and Kinetic Studies of Peptidic Antagonists of CBX Chromodomains